secwatch.observer — SEC 8-K summary
======================================

Issuer:     Schrodinger, Inc. (SDGR)
CIK:        0001490978
Form:       8-K
Filed at:   2021-08-12T23:59:59+00:00
Accession:  0000950123-21-010437
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Schrödinger Q2 revenue up 29% to $29.8M; net loss widens to $34.6M on investment spend
--------------------------------------------------------------------------------

- Total revenue $29.8M (+29% YoY); software revenue $24.1M (+15% YoY); drug discovery revenue $5.7M.
- Net loss $34.6M vs $3.4M loss Q2 2020, driven by fair-value adjustments and R&D investments.
- Announced global oncology collaboration with Zai Lab; eligible for up to ~$338M milestones and U.S. profit share.
- Pipeline advancing: plans to submit up to three INDs to FDA in 2022, first IND expected H1 2022.
- Full-year 2021 guidance maintained: total revenue $124M-$142M, software revenue $102M-$110M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1490978/000095012321010437/0000950123-21-010437-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1490978/000095012321010437/FINAL-sdgr-8k_20210812.htm
  HTML page:      https://secwatch.observer/filing/0000950123-21-010437

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer